1 June 2023 - Pharming announces that it has entered into a definitive agreement with Novartis to sell its rare paediatric disease priority review voucher to Novartis for a pre-agreed, one-time payment of approximately US$21.1 million shortly after closing.

Pharming was granted the voucher by the FDA in March 2023 in connection with the approval of Joenja (leniolisib); an oral, selective PI3Kδ inhibitor, for activated phosphoinositide 3-kinase delta syndrome in adult and paediatric patients 12 years of age and older.

Pursuant to the terms of the August 2019 exclusive license agreement between Pharming and Novartis for leniolisib, Novartis has the right to purchase the voucher from Pharming for a pre-agreed, contractually defined percentage of the voucher value.

Read Pharming press release